Pharmaceutical Preparations · L3 · CIK 1668243
UroGen Pharma develops and commercializes innovative solutions for urothelial and specialty cancers using its RTGel technology
Comparable business profile · signals at a glance
In the 90 days to Feb 3, 2026: 2 sold $542K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 3, 2026 | Schoenberg MarkChief Medical Officer | Sell | 3,686 | $19.69 | $73K |
| Feb 3, 2026 | Smith Jason DrewGeneral Counsel | Sell | 3,217 | $19.69 | $63K |
| Feb 3, 2026 | Smith Jason DrewGeneral Counsel | Sell | 2,654 | $19.69 | $52K |
| Feb 3, 2026 | Schoenberg MarkChief Medical Officer | Sell | 1,844 | $19.69 | $36K |
| Feb 3, 2026 | Schoenberg MarkChief Medical Officer | Sell | 1,843 | $19.69 | $36K |
| Feb 3, 2026 | Smith Jason DrewGeneral Counsel | Sell | 1,608 | $19.69 | $32K |
| Nov 19, 2025 | Schoenberg MarkChief Medical Officer | Sell | 10,000 | $25.00 | $250K |
| Oct 8, 2025 | Degnan ChrisChief Financial Officer | Sell | 2,203 | $16.85 | $37K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.